Spencer Ross
Growth, special situations, long only

AtriCure Mid-Trial Results Highly Encouraging

AtriCure Inc. (NSDQ:ATRC), a maker of medical devices used in atrial fibrillation today announced encouraging mid-term results in an unofficial trial for persistent Afib (atrial fibrillation) in Europe which may bode well for the company going forward.

Atrial fibrillation, often referred to as "afib," is an irregular heartbeat, a rapid heartbeat, or a quivering of the upper chambers of the heart, called the atria. Atrial fibrillation is due to a malfunction in the heart's electrical system, and is the most common heart irregularity, or cardiac arrhythmia. Afib is an irregular heart beat that affects up to 2% of the world's population.

As we age, the incidence of atrial fibrillation increases. As Baby Boomers continue to age, we can...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details